- Mechanism
- Induces apoptosis in senescent cells via FOXO4-p53 disruption
- Typical research dose
- 1-5 mg/kg in murine models
- Route
- subcutaneous
- Half-life
- Unknown (extended via DRI modification)
- Legal status
- Research Only
Overview
FoxO4-DRI (Proxofim) is a synthetic senolytic peptide engineered to selectively clear damaged, aging cells from the body. By disrupting the binding between the FOXO4 protein and the p53 tumor suppressor, the FoxO4-DRI peptide forces dysfunctional cells into apoptosis without harming healthy tissue. This targeted clearance reduces chronic inflammation and the senescence-associated secretory phenotype (SASP), making it a critical focus in longevity research for its potential to restore tissue homeostasis and mitigate age-related decline.
Potential Benefits
- Targeted Senescent Cell Clearance: The peptide selectively removes senescent cells from tissues, such as in vitro expanded human chondrocytes, without harming healthy cells (Huang et al., 2021).
- Amelioration of Pulmonary Fibrosis: By targeting myofibroblasts and reducing extracellular matrix production, it ameliorates bleomycin-induced pulmonary fibrosis in mice (Han et al., 2022).
- Restoration of Testosterone Secretion: Targeting senescent Leydig cells alleviates age-related testosterone insufficiency and improves spermatogenesis in aged murine models (Li et al., 2024).
- Radiosensitization of Cancer Cells: Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis (Meng et al., 2021).
- Reduction of Keloid Scarring: It induces apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of upregulated p53, offering potential for scar treatment (Kong et al., 2025).
- Endothelial Function Support: Research demonstrates that it regulates endothelial cell senescence via the P53 signaling pathway, potentially supporting vascular health (Hu et al., 2025).
Where to Buy FoxO4-DRI
Ascension Peptides
View →Research compound. FoxO4-DRI is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site reactions including redness or swelling
- Mild fatigue or lethargy post-administration
- Temporary changes in blood pressure
- Headaches or mild dizziness
- Localized tissue sensitivity
Rare or serious side effects:
- Potential promotion of pulmonary hypertension development (Born et al., 2023)
- Off-target apoptosis in highly stressed but non-senescent cells
- Unintended interference with normal p53 tumor suppressor functions
- Severe immune or allergic response to the synthetic peptide
FoxO4-DRI is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
FOXO4-p53 Interaction Disruption is the primary mechanism by which the FoxO4-DRI peptide exerts its senolytic effects. In senescent cells, the FOXO4 protein binds to the p53 tumor suppressor, sequestering it in the nucleus and preventing it from initiating apoptosis. By utilizing a D-Retro-Inverso (DRI) conformation, the peptide mimics the binding domain of FOXO4, competitively binding to the disordered p53 transactivation domain (Bourgeois et al., 2025). This action releases p53, allowing it to translocate to the mitochondria and trigger cell death specifically in damaged, senescent cells.
Selective Apoptosis Induction ensures that healthy cells remain unaffected during treatment. Because normal cells do not exhibit the elevated FOXO4-p53 nuclear localization seen in senescence, the peptide selectively targets only those cells contributing to the senescence-associated secretory phenotype (SASP). This targeted clearance reduces chronic inflammation and allows surrounding healthy cells to proliferate and repair tissue, as observed in studies ameliorating pulmonary fibrosis (Liu et al., 2023).
Origin & History
Discovery and Development of FoxO4-DRI originated from research into the molecular hallmarks of aging and cellular senescence, notably pioneered by researchers like Peter de Keizer (Baar et al., 2017). Scientists identified that senescent cells rely on the FOXO4-p53 axis to evade apoptosis, leading to the design of a synthetic peptide that could disrupt this specific protein-protein interaction. The D-Retro-Inverso modification was incorporated to enhance the peptide's stability and resistance to proteolytic degradation in vivo, making it a viable candidate for anti-aging and regenerative research.
Regulatory Status and Future Research dictate that FoxO4-DRI remains strictly an experimental compound. It is currently designated for research-only purposes and has not been approved by the FDA for human use. Ongoing preclinical studies continue to evaluate FoxO4-DRI side effects and therapeutic potential, particularly its ability to clear senescent cells in age-related diseases, cancer radiosensitization, and fibrotic conditions.